Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 7/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.56 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.52 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25335885 | 1.00 | BDKRB2 (0.68) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| SCHEMBL30672603 | 0.99 | BDKRB2 (0.66) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| SCHEMBL31289571 | 0.99 | BDKRB2 (0.66) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| SCHEMBL31289572 | 0.98 | BDKRB2 (0.66) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| SCHEMBL30672572 | 0.97 | BDKRB2 (0.72) | BDKRB2OPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL30549403 | 0.96 | BDKRB2 (0.63) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| SCHEMBL30526200 | 0.94 | BDKRB2 (0.61) | BDKRB2OPRM1OPRD1F2C5AR1 | |
| Bradykinin SCHEMBL7949679 | 0.94 | BDKRB2 (0.67) | BDKRB2OPRM1OPRD1F2NMUR2 | |
| Bradykinin SCHEMBL7949684 | 0.94 | BDKRB2 (0.67) | BDKRB2OPRM1OPRD1F2NMUR2 | |
| SCHEMBL29496923 | 0.94 | BDKRB2 (0.62) | BDKRB2OPRM1OPRD1F2C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-12558420-B2 | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | SANOFI (FR) | 2026-02-24 | — | — | US | disclosed |
| EP-4596689-A1 | ENZYME AGENT AND USE THEREOF | Amano Enzyme Inc. (JP) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025147774-A1 | COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING AND TREATMENT OF CANCER AND OTHER DISORDERS | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-17 | — | — | WO | disclosed |
| CN-120092086-A | Enzyme agent and application thereof | 天野酶制品株式会社 | 2025-06-03 | — | — | CN | disclosed |
| WO-2024071388-A1 | ENZYME AGENT AND USE THEREOF | 天野エンザイム株式会社 | 2024-04-04 | — | — | WO | disclosed |
| US-20230399388-A1 | METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN | SANOFI (FR) | 2023-12-14 | — | — | US | disclosed |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | OPRK1, TPH1, HTR3C | BDKRB2 102/4885OPRM1 36/4885OPRD1 18/4885 |
| US-12558420-B2 | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | BDKRB2, KLKB1, BDKRB1 | BDKRB2 1/4885OPRM1 945/4885OPRD1 819/4885 |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TPH1, TPH2, SYMPK | BDKRB2 101/4885OPRM1 634/4885OPRD1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.